BARDA continues long-standing partnerships with GSK, Sanofi, and Seqirus to strengthen preparedness and rapid response capabilities for influenza pandemics


WEB ANNOUNCEMENT
About Image

BARDA is continuing partnerships with industry collaborators GlaxoSmithKline (GSK), Sanofi, and Seqirus to strengthen pandemic preparedness and response capabilities by ensuring ready production of medical countermeasures (MCMs), such as influenza vaccines and adjuvants, in the event of an influenza pandemic or other public health emergency.

The U.S. Department of Health and Human Services (HHS) continuously monitors pandemic risk in order to prepare to respond to the threats posed by novel influenza, including outbreaks caused by zoonotic influenza viruses. Within BARDA’s Division of Influenza and Emerging Infectious Diseases (IEID), the National Pre-pandemic Influenza Vaccine Stockpile (NPIVS) provides preparedness for influenza pandemics and maintains stockpiles of influenza vaccine antigens and adjuvants. The IEID Division works closely with its interagency partners and performs risk assessments to identify and evaluate potential pandemic influenza virus threats.

BARDA maintains the NPIVS inventory through public-private partnerships with domestic manufacturers of licensed influenza vaccines using egg-, recombinant protein-, cell-based vaccine, and oil-in-water adjuvant technologies. These partnerships seek to shorten timelines to make influenza vaccines available for the U.S. population in response to a pandemic.

Since 2005, BARDA has awarded contracts to domestic and licensed influenza vaccine manufacturers to sustain and expand the dynamic pre-pandemic influenza vaccine stockpile. This approach allows fast and continuous updates of pre-pandemic vaccines and adjuvants stockpiled for pandemic preparedness and enables a rapid response.

This partnership will build on the foundation laid out by the U.S. government’s previous investments and is aligned with the Executive Order (EO) 13887 on Modernizing Influenza Vaccines in the United States to Promote National Security and Public Health. The National Influenza Vaccine Modernization Strategy (NIVMS), 2020-2030, also outlines a vision for the U.S. influenza vaccine enterprise to be highly responsive, flexible, resilient, scalable, and more effective at reducing the impact of seasonal and pandemic influenza viruses.

These Indefinite Delivery Indefinite Quantity (IDIQ) contracts will provide BARDA with flexible and immediate access to MCMs, such as vaccines and adjuvants, for pandemic preparedness and response or as required in response to an HHS-declared Public Health Emergency; production of vaccines against influenza viruses and strains with pandemic potential; and production of vaccines and adjuvants to support U.S. government efforts to modernize influenza virus vaccines.

About GSK:

The following information is provided by the company and does not indicate endorsement by the federal government of the company or its products.

GSK is a science-led global healthcare company. For further information, please visit www.gsk.com/about-us.

 

About Sanofi:

The following information is provided by the company and does not indicate endorsement by the federal government of the company or its products.

We are an innovative global healthcare company, driven by one purpose: we chase the miracles of science to improve people’s lives. Our team, across some 100 countries, is dedicated to transforming the practice of medicine by working to turn the impossible into the possible. We provide potentially life-changing treatment options and life-saving vaccine protection to millions of people globally, while putting sustainability and social responsibility at the center of our ambitions. https://www.sanofi.us/en/about-us

 

About Seqirus:

The following information is provided by the company and does not indicate endorsement by the federal government of the company or its products.

Derived from the expression 'securing health for all of us', Seqirus has public health protection at its core. This reflects the promise of our parent company CSL, founded in 1916 to save lives and protect the health of people. Our first true test came with the Spanish Influenza Pandemic and we have been committed to the fight against influenza ever since. 

Influenza kills. But at Seqirus, we believe it shouldn’t be that way. As the only vaccine company with a singular global focus on influenza, we work tirelessly on cutting-edge research, transformative technologies and the latest methods of production and distribution. Together with our partners we’re on the front line every day, protecting communities from seasonal influenza and global pandemic threats.

Our vision is a world protected from influenza.  https://www.seqirus.com/our-company

Last Updated: February 25, 2022

IEID Portfolio

This award is one component of BARDA's expanding Influenza & Emerging Infectious Disease Portfolio; visit BARDA's IEID Portfolio to learn more.